Ultragenyx is a biotechnology business based in the US. Ultragenyx shares (RARE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $45.13 – a decrease of 5.27% over the previous week. Ultragenyx employs 1,276 staff and has a trailing 12-month revenue of around $522.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $45.13 |
|---|---|
| 52-week range | $37.02 - $60.37 |
| 50-day moving average | $54.64 |
| 200-day moving average | $48.08 |
| Wall St. target price | $92.57 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $45.13 from 2024-11-19
| 1 week (2024-11-14) | -5.27% |
|---|---|
| 1 month (2024-10-21) | -17.13% |
| 3 months (2024-08-21) | -20.89% |
| 6 months (2024-05-21) | 11.21% |
| 1 year (2023-11-21) | 16.19% |
|---|---|
| 2 years (2022-11-21) | 31.31% |
| 3 years (2021-11-19) | 79.32 |
| 5 years (2019-11-21) | 17.43% |
| Revenue TTM | $522.7 million |
|---|---|
| Gross profit TTM | $-370,780,000 |
| Return on assets TTM | -24.12% |
| Return on equity TTM | -289.98% |
| Profit margin | -106.93% |
| Book value | $3.76 |
| Market Capitalization | $4.4 billion |
TTM: trailing 12 months
We're not expecting Ultragenyx to pay a dividend over the next 12 months.
Ultragenyx's shares were split on a 1:3 basis on 16 January 2014 . So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ultragenyx shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Ultragenyx shares which in turn could have impacted Ultragenyx's share price.
Over the last 12 months, Ultragenyx's shares have ranged in value from as little as $37.02 up to $60.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ultragenyx's is 0.581. This would suggest that Ultragenyx's shares are less volatile than average (for this exchange).
Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co. , Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.